Compare Bristol-Myers Squibb Co (BMY) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Invesco NASDAQ 100 ETF — how do they compare? Bristol-Myers Squibb Co trades at $58.31 (market cap $116.30B), while Invesco NASDAQ 100 ETF trades at $296.88. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Invesco NASDAQ 100 ETF pays none. Which is the better fit depends on your goals.
| BMY | QQQM | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $62.37 | $307.23 |
52-Week Low | $42.60 | $228.02 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
QQQM, tracking the Nasdaq-100, trades at $293.06, down 1.89% on the day amid a bearish technical signal from moving averages. The ETF's valuation ratios are unavailable, but it offers exposure to major tech firms, with recent news highlighting SpaceX's inclusion in the index. Support lies at $292, with resistance at $295.
The outlook is cautious due to stretched valuations and AI competition risks, but QQQM's lower expense ratio than QQQ provides a cost edge. Key risks include market volatility and sector concentration, while analyst sentiment is mixed, with some seeing long-term growth potential from AI infrastructure spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
